Payment overview · 2025
General Payments
$77,297.11
318 reported records · 38 companies
Healthcare provider profile · identity verified
Derek R Smith, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · NORWICH, CT · NPI 1407869019
Verified facts
What the public records show
CMS Open Payments records show Derek R Smith, MD received $77,297.11 in general payments during 2025 across 318 reported records.
TG Therapeutics, Inc. accounted for 69.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 47 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt, Ocrevus, Tysabri, Vumerity.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TECFIDERA as an associated drug or biological on 28 records involving 22 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Tecfidera by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TYSABRI as an associated drug or biological on 12612 records involving 3572 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Tysabri by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vumerity by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ocrevus as an associated drug or biological on 3064 records involving 1133 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ocrevus by this doctor in 2024.
Genentech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ocrevus as an associated drug or biological on 450 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ocrevus by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MAYZENT as an associated drug or biological on 26 records involving 26 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mayzent by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $53,681.68 | 69.5% | 39 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $11,618.67 | 15.0% | 29 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $2,703.73 | 3.5% | 32 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $2,428.27 | 3.1% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $573.77 | 0.7% | 14 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $552.28 | 0.7% | 30 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $493.19 | 0.6% | 22 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $490.48 | 0.6% | 24 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $475.29 | 0.6% | 13 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $457.26 | 0.6% | 19 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $336.83 | 0.4% | 8 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $335.28 | 0.4% | 8 | 2025 |
| Genentech, Inc. | Unresolved — no canonical attribution shown | $335.05 | 0.4% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $330.24 | 0.4% | 5 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $300.90 | 0.4% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $263.03 | 0.3% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $255.77 | 0.3% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $191.70 | 0.2% | 5 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $181.89 | 0.2% | 11 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $162.32 | 0.2% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $160.72 | 0.2% | 3 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $143.07 | 0.2% | 4 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $124.18 | 0.2% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $123.18 | 0.2% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $107.02 | 0.1% | 5 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $76.26 | 0.1% | 3 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$58.97 | 0.1% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $50.48 | 0.1% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.20 | 0.1% | 2 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $37.76 | 0.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.19 | 0.0% | 2 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $29.89 | 0.0% | 1 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $27.09 | 0.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $26.47 | 0.0% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $25.42 | 0.0% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $23.60 | 0.0% | 1 | 2025 |
| Life Molecular Imaging Ltd | Unresolved — no canonical attribution shown | $20.75 | 0.0% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $17.23 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $60,827.50 | 19 |
| Food and Beverage | $9,507.63 | 282 |
| Travel and Lodging | $3,478.56 | 10 |
| Consulting Fee | $3,446.00 | 5 |
| Education | $37.42 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $53,681.68 | 39 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $10,818.37 | 20 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $2,561.77 | 14 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $1,095.71 | 22 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $552.28 | 30 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $475.29 | 13 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $473.58 | 21 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $415.70 | 18 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $411.90 | 17 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $373.10 | 3 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $370.39 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $330.06 | 16 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $303.17 | 14 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc., Genentech, Inc. | $269.19 | 5 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $263.03 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $247.06 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $223.86 | 7 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $205.44 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $191.70 | 5 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $187.31 | 10 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $167.90 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $160.72 | 3 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $143.07 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $136.93 | 6 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $124.80 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $124.18 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $123.18 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $111.42 | 1 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $108.69 | 2 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $107.02 | 5 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $76.26 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $53.84 | 2 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $50.48 | 2 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $48.39 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc., PFIZER INC. | $45.03 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $43.20 | 2 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $37.76 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $34.19 | 2 | 2025 |
Source payment records
|
|||||
| AQUACEL AG+ EXTRA Normalized: aquacel ag extra |
Device | ConvaTec Inc. | $27.09 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $26.47 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $23.60 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $23.20 | 1 | 2025 |
Source payment records
|
|||||
| NEURACEQ Normalized: neuraceq |
Drug | Life Molecular Imaging Ltd | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $20.73 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $17.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 74 | exact normalized | Medicare Part D |
| Ocrevus ocrevus |
2025 | Ocrevus | 2024 | 32 | exact normalized | Medicare Part D |
| TYSABRI tysabri |
2025 | Tysabri | 2024 | 78 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TECFIDERA open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 22 recipient NPIs · example record 1208304358 |
Tecfidera · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TYSABRI open payments reported associated product |
CMS Open Payments — General Payments 12612 supporting records · 3572 recipient NPIs · example record 1208299693 |
Tysabri · 2024 Exact normalized brand match · 1 Part D row |
78 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Ocrevus open payments reported associated product |
CMS Open Payments — General Payments 3064 supporting records · 1133 recipient NPIs · example record 1211488404 |
Ocrevus · 2024 Exact normalized brand match · 1 Part D row |
32 | 19 |
| Genentech, Inc. Exact reporting entity; no affiliate inference |
2025 | Ocrevus open payments reported associated product |
CMS Open Payments — General Payments 450 supporting records · 299 recipient NPIs · example record 1211488540 |
Ocrevus · 2024 Exact normalized brand match · 1 Part D row |
32 | 19 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | MAYZENT open payments reported associated product |
CMS Open Payments — General Payments 26 supporting records · 26 recipient NPIs · example record 1200006493 |
Mayzent · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
74 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Baclofen | Baclofen | 272 | 67 |
| Gabapentin | Gabapentin | 183 | 47 |
| Clonazepam | Clonazepam | 181 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 136 | 29 |
| Zonisamide | Zonisamide | 123 | 33 |
| Dalfampridine Er | Dalfampridine | 118 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 107 | 20 |
| Tysabri | Natalizumab | 78 | suppressed |
| Fingolimod | Fingolimod Hcl | 77 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 74 | 21 |
| Dimethyl Fumarate | Dimethyl Fumarate | 66 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 60 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 53 | 22 |
| Levetiracetam | Levetiracetam | 52 | 12 |
| Diazepam | Diazepam | 50 | 13 |
| Glatiramer Acetate | Glatiramer Acetate | 48 | suppressed |
| Kesimpta Pen | Ofatumumab | 46 | suppressed |
| Lorazepam | Lorazepam | 46 | 18 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 44 | suppressed |
| Topiramate | Topiramate | 41 | suppressed |
| Armodafinil | Armodafinil | 40 | 11 |
| Modafinil | Modafinil | 39 | suppressed |
| Tecfidera | Dimethyl Fumarate | 36 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 33 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 33 | 15 |
| Eletriptan Hbr | Eletriptan Hydrobromide | 33 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 32 | suppressed |
| Ocrevus | Ocrelizumab | 32 | 19 |
| Teriflunomide | Teriflunomide | 27 | suppressed |
| Amantadine | Amantadine Hcl | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 21 | suppressed |
| Copaxone | Glatiramer Acetate | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Mayzent | Siponimod | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Glatopa | Glatiramer Acetate | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Lisinopril | Lisinopril | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Gilenya | Fingolimod Hcl | 12 | suppressed |
| Vumerity | Diroximel Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $77,297.11 · 318 records | TG Therapeutics, Inc. | ACTHAR, AQUACEL AG+ EXTRA, AUSTEDO XR, BOTOX, BRIUMVI, Bafiertam, COBENFY, FANAPT, Fintepla, Gamunex-C, Hizentra, INFINITY, INGREZZA, KESIMPTA, KISUNLA, LYBALVI, Leqembi, Mavenclad, NEURACEQ, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus, Ocrevus Zunovo, PANZYGA, PONVORY, PURIFIED CORTROPHIN GEL, QULIPTA, QUTENZA, REXULTI, Radicava, Rystiggo, Sunosi, Symbravo, TYSABRI, Tascenso ODT, UBRELVY, ULTOMIRIS, UPLIZNA, VUMERITY, VYEPTI, VYVGART, VYVGART HYTRULO, WAINUA, ZAVZPRET, ZEPOSIA, Zilbrysq | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Biogen, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error